FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement.
The drug will be available as a prescription-based medication for Rs 103/tablet, with recommended dose being 1,800 mg twice on day one, followed by 800 mg twice daily up to day 14.
Favipiravir can be used for coronavirus patients with co-morbid conditions such as diabetes and heart disease with mild to moderate COVID-19 symptoms.
It offers rapid reduction in viral load within four days and provides faster symptomatic and radiological improvement, the drug maker added.